Auvinen P, Lipponen P, Johansson R, Syrjänen K
Department of Pathology, University of Kuopio, Finland.
Anticancer Res. 1995 Nov-Dec;15(6B):2627-31.
A series of 273 breast cancer biopsies were analysed immunohistochemically for the expression of transforming growth factor beta-1 (TGF-beta 1) and beta-2 (TGF-beta 2) as related to standard prognostic factors and patient survival. TGF-beta 1 expression was found in 160/273 (59%) and TGF-2 in 110/273 (40%) of tumour specimens. Both isoforms were expressed in 89/273 (33%) of cases. TGF-beta 1 alone was expressed in 71/273 (26%) of cases and TGF-beta 2 alone was expressed in 19/273 (7%) of cases. The expression of TGF-beta 1 and TGF-beta 2 were both uniformly related to some other favourable prognostic factors. The expression of TGF-beta 2 without the expression of TGF-1 was significantly related to favourable disease outcome. The result of this study is in agreement with the previous studies of TGF-beta mRNA and also in vitro studies, but the result differs from some previous immunohistological studies. This study also suggests that the expression of TGF beta may have independent prognostic value over the expression of TGF-beta 1.
对273份乳腺癌活检样本进行免疫组织化学分析,以检测转化生长因子β-1(TGF-β1)和β-2(TGF-β2)的表达,并分析其与标准预后因素及患者生存率的关系。在160/273(59%)的肿瘤样本中发现了TGF-β1的表达,在110/273(40%)的样本中发现了TGF-β2的表达。在89/273(33%)的病例中两种异构体均有表达。仅TGF-β1表达的病例有71/273(26%),仅TGF-β2表达的病例有19/273(7%)。TGF-β1和TGF-β2的表达均与其他一些有利的预后因素一致相关。TGF-β2表达而TGF-β1不表达与良好的疾病转归显著相关。本研究结果与先前关于TGF-β mRNA的研究以及体外研究一致,但与一些先前的免疫组织学研究结果不同。本研究还表明,TGF-β的表达可能比TGF-β1的表达具有独立的预后价值。